Boron Neutron Capture Therapy and Nanotechnology
Toward the Revolutionized Cancer Therapy

研究概要

Radio

Boron Neutron Capture Therapy

Boron Neutron Capture Therapy (BNCT) is a radiation therapy that uses the nuclear reaction between thermal neutrons and boron (Boron-10), to kill cancer cells with the alpha particles and lithium nuclei produced.
When a drug containing boron is administered to the body and irradiated with neutrons, cancer cells are destroyed by the energy released from the boron. The area of effect is localized, and cancer cells can be destroyed while minimizing damage to normal cells. Conventional radiotherapy requires multiple irradiations, but BNCT is expected to be highly effective even with a single irradiation.

Learn more about BNCT

Nano

Nanotechnology

To further enhance the therapeutic effect of this BNCT, we have developed a new product called RN-501, a highly hydrophilic boron-containing inorganic nanoparticles.
The product is designed to deliver to cancer cells in a concentrated manner, which not only reduces side effects, but also makes it applicable to carcinomas that have been difficult to treat. In addition, the product's high accumulation and retention properties enable treatment at lower doses and for shorter periods of time than conventional formulations.

Learn more about nanotechnology

Nanotechnology to enhance the advantages of BNCT
A Next-Generation Radiotherapy
that could be the First Choice for Cancer Treatment.

Our Mission

Contribute to the health and future of cancer patients and their families through the development of novel biologically targeted radiation therapy

RadioNano Therapeutics Inc., a venture company, was established for the social implementation of Boron Neutron Capture Therapy (BNCT) using highly hydrophilic boron-containing inorganic nanoparticles developed by Professor Naoki Komatsu of the Graduate School of Human and Environmental Studies, Kyoto University and Professor Minoru Suzuki of the Institute for Composite Nuclear Science, Kyoto University.

NEWS

As a supplementary prize for receiving the Grand Prize from Ikeda Senshu Bank, we participated in a recording of MBS Radio’s program “Nippon Ichi Akarui Keizai Denpa Shimbun.”

We are pleased to announce that we have received the Grand Prize in an award program hosted by Ikeda Senshu Bank. As a supplementary prize, our Representative Director, Mr. Chiba, participated in a recording of the MBS Radio program “Nippon Ichi Akarui Keizai Denpa Shimbun” (Editor-in-Chief: Nobuo Takehara; Announcer: Hiroko Matsukawa). During the recording, we had the opportunity to discuss the initiatives that led to the award, our commitment to our business, and our future

Apr 17

The award ceremony for the Grand Prize of the 22nd Innovation Research and Development Grants, hosted by Ikeda Senshu Bank Co., Ltd., was held.

The award ceremony for the 22nd Innovation Research & Development Grant , organized by The Ikeda Senshu Bank, Ltd. , was held, and our President and Chief Executive Officer, Mr. Chiba , attended the ceremony. This grant program aims to revitalize local communities by fostering the creation of new businesses through support for innovative and highly original business plans, as well as advanced research and development initiatives that contribute to solving social and regional

Mar 30

Our company has been featured on the official website of Kyoto University Innovation Capital Co., Ltd.

A conversation between our Representative Director and President, Masatoshi Chiba, and Professor Naoki Komatsu of the Graduate School of Human and Environmental Studies at Kyoto University — who is the inventor of the technology and serves as our Outside Director and Scientific Advisory Board Member — has been published on the official website of Kyoto University Innovation Capital Co., Ltd. The discussion covers the background of the development and its current progress. Kyo

Mar 19

RadioNano Therapeutics Inc. have been certified as a 'Kyoto City A-Rank Recognized Company' by the 65th Kyoto City Venture Enterprise Screening Committee for fiscal year 2025.

The Kyoto City Venture Enterprise Screening Committee is a program established by the City of Kyoto to discover and nurture venture companies that will drive the industries of the next generation, comprehensively evaluating new business plans based on criteria such as novelty, business viability, market potential, and management philosophy. In this screening, we received high recognition for the novelty and innovation of our proprietary RN-501 technology, as well as the uniqu

Mar 15

2 3 4